Assignee
Dermavant Sciences GmbH
CH·21 granted patents·17 pending applications·50 citations·filing 2015–2025
Top patents by PatentIndex Score
38 records- 0193US10195160B2Topical pharmaceutical compositionsDermavant Sciences GmbH·Filed 2016·Granted Feb 5, 2019·21 cites·113 claims
- 0291US11590088B2Use of Tapinarof for the treatment of chronic plaque psoriasisDermavant Sciences GmbH·Filed 2022·Granted Feb 28, 2023·3 cites·22 claims
- 0390US11827605B2Isoquinoline compounds and their use in treating AhR imbalanceDermavant Sciences GmbH·Filed 2022·Granted Nov 28, 2023·1 cites·18 claims
- 0490US10961175B2Process for preparing tapinarofDermavant Sciences GmbH·Filed 2020·Granted Mar 30, 2021·3 cites·23 claims
- 0588US10647649B2Process for preparing tapinarofDermavant Sciences GmbH·Filed 2018·Granted May 12, 2020·3 cites·66 claims
- 0687US11622945B2Topical pharmaceutical compositionsDermavant Sciences GmbH·Filed 2018·Granted Apr 11, 2023·2 cites·29 claims
- 0786US11267788B2Isoquinoline compounds and their use in treating AhR imbalanceDermavant Sciences GmbH·Filed 2021·Granted Mar 8, 2022·1 cites·10 claims
- 0885US11617724B2Topical pharmaceutical compositionsDermavant Sciences GmbH·Filed 2017·Granted Apr 4, 2023·2 cites·46 claims
- 0985US10426743B2Topical pharmaceutical compositionsDermavant Sciences GmbH·Filed 2019·Granted Oct 1, 2019·4 cites·116 claims
- 1083US12252471B2Isoquinoline compounds and their use in treating AhR imbalanceDermavant Sciences GmbH·Filed 2023·Granted Mar 18, 2025·0 cites·7 claims
- 1183US11458108B2Topical pharmaceutical compositionsDermavant Sciences GmbH·Filed 2018·Granted Oct 4, 2022·1 cites·31 claims
- 1280US11938099B2Use of tapinarof for the treatment of atopic dermatitisDermavant Sciences GmbH·Filed 2023·Granted Mar 26, 2024·0 cites·15 claims
- 1379US10376475B2Method of useDermavant Sciences GmbH·Filed 2015·Granted Aug 13, 2019·8 cites·30 claims
- 1478US12275696B2Process for preparing tapinarofDermavant Sciences GmbH·Filed 2023·Granted Apr 15, 2025·0 cites·18 claims
- 1578US2024285550A1Topical pharmaceutical compositionsDermavant Sciences GmbH·Filed 2024·Application pending·0 cites
- 1677US12569453B2Use of tapinarof for the treatment of atopic dermatitisDermavant Sciences GmbH·Filed 2023·Granted Mar 10, 2026·0 cites·20 claims
- 1775US11548853B2Isoquinoline compounds and their use in treating AhR imbalanceDermavant Sciences GmbH·Filed 2022·Granted Jan 10, 2023·0 cites·23 claims
- 1874US11612573B2Topical pharmaceutical compositionsDermavant Sciences GmbH·Filed 2019·Granted Mar 28, 2023·0 cites·26 claims
- 1974US2025270158A1Process for preparing tapinarofDermavant Sciences GmbH·Filed 2025·Application pending·0 cites
- 2073US2023126208A1Topical pharmaceutical compositionsDermavant Sciences GmbH·Filed 2022·Application pending·0 cites
- 2172US11497718B2Use of tapinarof for the treatment of atopic dermatitisDermavant Sciences GmbH·Filed 2019·Granted Nov 15, 2022·0 cites·21 claims
- 2272US2025282730A1ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCEDermavant Sciences GmbH·Filed 2025·Application pending·0 cites
- 2371US10357495B2Topical formulations of PDE-4 inhibitors and their methods of useDermavant Sciences GmbH·Filed 2019·Granted Jul 23, 2019·1 cites·40 claims
- 2470US11597692B2Process for preparing tapinarofDermavant Sciences GmbH·Filed 2021·Granted Mar 7, 2023·0 cites·12 claims
- 2563US2023106782A1Use of tapinarof for the treatment of chronic plaque psoriasisDermavant Sciences GmbH·Filed 2022·Application pending·0 cites
- 2662US2020147000A1Use of tapinarof for the treatment of chronic plaque psoriasisDermavant Sciences GmbH·Filed 2019·Application pending·0 cites
- 2759US10206925B2Topical formulations of PDE-4 inhibitors and their methods of useDermavant Sciences GmbH·Filed 2017·Granted Feb 19, 2019·0 cites·40 claims
- 2855US2026069553A1TAPINAROF AND ANALOGS THEREOF FOR USE IN TREATING AhR MEDIATED DISEASESDermavant Sciences GmbH·Filed 2023·Application pending·0 cites
- 2955US2026069585A1ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASESDermavant Sciences GmbH·Filed 2023·Application pending·0 cites
- 3054US2024315985A1Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitisDermavant Sciences GmbH·Filed 2022·Application pending·0 cites
- 3154US2022265572A1Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitisDermavant Sciences GmbH·Filed 2022·Application pending·0 cites
- 3251US2021260055A1Topical formulations of dgat1 inhibitors and their methods of useDermavant Sciences GmbH·Filed 2019·Application pending·0 cites
- 3349US2022395472A1Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitisDermavant Sciences GmbH·Filed 2022·Application pending·0 cites
- 3449US2022160650A1Gel, ointment, and foam formulations of tapinarof and methods of useDermavant Sciences GmbH·Filed 2021·Application pending·0 cites
- 3548US2020390689A1Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereofDermavant Sciences GmbH·Filed 2019·Application pending·0 cites
- 3647US2023225987A1Topical pharmaceutical compositionsDermavant Sciences GmbH·Filed 2021·Application pending·0 cites
- 3744US2021093637A1Topical ointment formulations of pde-4 inhibitor and their use in treating skin conditionsDermavant Sciences GmbH·Filed 2018·Application pending·0 cites
- 3842US2022233534A1Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereofDermavant Sciences GmbH·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Dermavant Sciences GmbH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →